Impavido is an oral medication containing miltefosine, primarily used to treat certain parasitic infections, particularly leishmaniasis. It functions by inhibiting the growth of the Leishmania parasites responsible for the disease.
Product Highlights
Management of visceral leishmaniasis, commonly referred to as kala-azar.
Treatment of cutaneous leishmaniasis.
Key Ingredient
Miltefosine
Key Benefits
Proven efficacy in treating leishmaniasis, including forms resistant to other treatments.
Oral formulation allows for easy dosing compared to intravenous alternatives.
Typically well-tolerated, with a manageable side effect profile.
Direction of Use
Follow the prescribed dosage regimen, typically taken once daily for a specific duration (usually 28 days for visceral leishmaniasis).
May be taken with or without food; however, consuming it with food might help lessen gastrointestinal side effects.
Miltefosine Dosage
Weight
Dosage and Administration
30 kg to 44 kg
One 50 mg capsule twice daily with food (breakfast and dinner)
45 kg or greater
One 50 mg capsule three times daily with food (breakfast, lunch, and dinner)
Safety Concerns
Frequent side effects may include nausea, vomiting, diarrhea, and stomach pain.
Regular monitoring may be necessary for liver function and potential hematological changes during treatment.
May interact with other medications; consult a healthcare provider for a full list of interactions.
Avoid Impavido (Miltefosine) If
You have a known allergy to miltefosine or any of its components.
You are pregnant or planning to become pregnant; effective contraception is recommended during treatment and for a period afterward.
You have severe liver or kidney dysfunction without consulting a healthcare provider.
You are breastfeeding without discussing the risks and benefits with a healthcare professional.
